Manhattan Biosolutions

Manhattan BioSolutions engineers next-generation antibody-drug conjugates (ADCs) inspired by evolutionary mechanisms, delivering unparalleled tumor targeting and payload release to conquer advanced cancers. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated or direct anti-tumor mechanisms